

Notices

Federal Register

Vol. 91, No. 153

Tuesday, August 11, 2026

This section of the FEDERAL REGISTER contains documents other than rules or proposed rules that are applicable to the public. Notices of hearings and investigations, committee meetings, agency decisions and rulings, delegations of authority, filing of petitions and applications and agency statements of organization and functions are examples of documents appearing in this section.

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-57-2026]

Foreign-Trade Zone (FTZ) 153; Withdrawal of Notification of Proposed Production Activity; Foxx Development, Inc.; (Production of Smartphones); San Diego, California

Notice is hereby given of the withdrawal of the notification of proposed production activity submitted by Foxx Development, Inc. for its facility in San Diego, California, within FTZ 153. The notification was docketed on May 27, 2026 (91 FR 34215, June 5, 2026). The withdrawal was requested by Foxx Development, Inc. on August 6, 2026.

Dated: August 7, 2026.

Elizabeth Whiteman,
Executive Secretary.

[FR Doc. 2026-16355 Filed 8-10-26; 8:45 am]

BILLING CODE 3510-DS-P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-100-2026]

Foreign-Trade Zone (FTZ) 61, Notification of Proposed Production Activity; Viatris Pharmaceuticals LLC; (Medications); Vega Baja, Puerto Rico

Viатris Pharmaceuticals LLC submitted a notification of proposed production activity to the FTZ Board (the Board) for its facility in Vega Baja, Puerto Rico within FTZ 61. The notification conforming to the requirements of the Board's regulations (15 CFR 400.22) was received on July 30, 2026.

Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material(s)/component(s) and specific finished

product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via www.trade.gov/ftz.

The proposed finished products include: ativan tablets, atorvastatin tablets, celebrex capsules; colestid tablets; Detrol capsules; Dilantin tablets and capsules; Effexor capsules; eplerenone tablets; ibranche capsules; inspra tablets; Lipitor tablets; lorbrenea tablets; lorviqua tablets; lyrica capsules; Neurontin tablets and capsules; nitrostat tablets; Norvasc tablets; Pristiq tablets; vizimpro tablets; Xanax immediate release tablets; Xeljanz extended release tablets; Zithromax tablets; and zyvox tablets (duty-free).

The proposed foreign-status materials/components include: amlodipine besylate active pharmaceutical ingredient (API); atorvastatin API; Ativan tablets; azithromycin API; calcium carbonate; Cardura bulk tablets; celecoxib API; dacomitinib tablets; Effexor capsules; eplerenone API; gabapentin API; Geodon capsules; microcrystalline cellulose; mini bags; pharmitose (lactose for atorvastatin/Lipitor); pregabalin API; propranolol API; pregabalin bulk capsules; rapamune tablets; tabletose; Xanax IR tablets; Xanax XR tablets; Zoloft tablets; disopyramide API; linezolid API; lorlatinib tablets; palbociclib tablets; Pristiq tablets; rapamune tablets; and, talazoparib tablets (duty rate ranges from duty-free to 8.4%).

The request indicates that certain materials/components are subject to duties under section 232 of the Trade Expansion Act of 1962 (section 232), depending on the country of origin. The applicable section 232 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41).

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is September 21, 2026.

A copy of the notification will be available for public inspection in the

“Online FTZ Information System” section of the Board's website.

For further information, contact Brian Warnes at brian.warnes@trade.gov.

Dated: August 7, 2026.

Elizabeth Whiteman,
Executive Secretary.

[FR Doc. 2026-16356 Filed 8-10-26; 8:45 am]

BILLING CODE 3510-DS-P

DEPARTMENT OF COMMERCE

International Trade Administration

[A-570-121]

Difluoromethane (R-32) From the People's Republic of China: Continuation of Antidumping Duty Order

AGENCY: Enforcement and Compliance, International Trade Administration, Department of Commerce.

SUMMARY: As a result of the determinations by the U.S. Department of Commerce (Commerce) and the U.S. International Trade Commission (ITC) that revocation of the antidumping duty (AD) order on difluoromethane (R-32) from the People's Republic of China (China) would likely lead to the continuation or recurrence of dumping and material injury to an industry in the United States, Commerce is publishing a notice of continuation of this AD order.

DATES: Applicable August 4, 2026.

FOR FURTHER INFORMATION CONTACT: Ajay Menon, AD/CVD Operations, Office IX, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482-0208.

SUPPLEMENTARY INFORMATION:

Background

On March 11, 2021, Commerce published in the **Federal Register** the AD order on R-32 from China.¹ On February 2, 2026, the ITC instituted,² and Commerce initiated,³ the first sunset review of the *Order*, pursuant to

¹ See *Difluoromethane (R-32) from the People's Republic of China: Antidumping Duty Order*, 86 FR 13886 (March 11, 2021) (*Order*).

² See *Difluoromethane (R-32) from China: Institution of a Five-Year Review*, 91 FR 4620 (February 2, 2026).

³ See *Initiation of Five-Year (Sunset) Reviews*, 91 FR 4499 (February 2, 2026).